| Objective: The acute coronary syndrome is a series of clinical syndromecaused by the acute myocardial ischemia. Coronary artery plaque vulnerabilityor unstabitily, is the pathological basis of clinical occurrence of acute coronarysyndrome (ACS). Visfatin (stimulated with visfatin), new discoveries in recentyears, adipocytokines, and atherosclerotic plaque formation, inflammationstatus, vascular endothelial dysfunction and other closely related ore and moreevidence that inflammation is an important mechanism of the ACS. Visfatin(stimulated with visfatin), new discoveries in recent years, adipocytokines,and atherosclerotic plaque formation, inflammation status, vascularendothelial dysfunction and other closely related. The Chemerin fat factor wasdiscovered in2007, has variety of biological effects, regulating themetabolism of fat cells, with pro-inflammatory role induced proliferation ofendothelial cells and nascent vascular plexus formation. And High-sensitivityC-reactive protein (hs-CRP), a reactive protein of acute inflammation ofsensitive and reliable response of the inflammatory changes in theatherosclerosis and coronary heart disease severity. Studies have shown thatPlasma stimulated with visfatin, chemerin may be coronary heart disease ofinflammatory cytokines involved in inflammation, the plaque becomesunstable and leads to the acute coronary syndrome.The high mortality rate andincidence of the disease, have made general public pay close attention to it.Atpresent, coronary heart disease was treat for western medicine, coronary arterybypass graft and intervention methods.However, in the field of Chinesemedicine researchless. For salvianolate research is mostly limited to animalexperiments for clinical research is not. Before and after the applicationsalvianolate through comprehensive evaluation, the efficacy of coronary heartdisease with acute coronary syndrome and visfatin, chemerin, high-sensitivity C-reactive protein (hs-CRP), levels of to explore salvianolate inarterialatherosclerosis development and progression of the role, to provide anew basis for the prevention and treatment of atherosclerosis, new treatmentmethods for the prediction of cardiovascular disease and treatment to open upnew prospects.Method:120patients with ACS, who came from The Second Hospital ofHebei Medical University, hospitalized by the Department ofCardiology,randomized divided into two groups,the treatment group,36malesand24females, aged38-78years old, with an average (60.05±1.26) years ofage, body mass index (BMI),(22.72±0.20) kg/m~2, and the control group,38males and22females, with an average (60.90±1.38)years of age, body massindex (BMI)(22.63±0.18) kg/m~2. All of the subjects except:(1) diabetes,hyperthyroidism, hyperlipidemia and other metabolic diseases;(2) the mergerof infectious diseases as respiratory infections, lung infections and so on;(3)malignant tumors, autoimmune system diseases application controlinflammation;(4) liver and kidney disease;(5) major surgery or trauma in amonth;(6) antipyretic analgesics, steroids and opiate drugs;(7) age>80yearsold, BMI≥25kg/m~2and <18.5kg/m~2was associated.All patients in age, sex,BMI, blood pressure, blood lipids, the differences were not statisticallysignificant. Selected patients with conventional acquisition history, routinelaboratory examination, routine use of aspirin, the nitrates agents, betablockers, statins, ACE inhibitors and other drugs. Treatment group, on thebasis of the control group to give salvianolate300mg, by adding5%glucose250ml intravenous infusion, once a day, the two groups are two weeks of acourse of treatment. All of the subjects on the day of admission,14days earlyin the morning fasting blood2ml, enzyme-linked immunosorbent assay(ELISA) was serum stimulated with visfatin, chemerin levels, the level ofimmune serum hs-CRP turbidimetric method. To observe the salvianolateefficacy in patients with coronary heart disease patients with acute coronarysyndrome and the change of visfatin, chemerin, high-sensitivity C-reactiveprotein (hs-CRP) levels before and after using the salvianolate. Result: Before treatment, the experimental group and control groupstimulated with age,sex,BMI,blood lipid were no significant differences(P>0.05). In the experimental group, after giving salvianolate the serum ofvisfatin, chemerin and hs-CRP were significantly lower than before treatment（6.89±0.13vs3.93±0.88）ng/mL，（225.98±2.03vs201.98±15.59）pg/L，（14.14±0.21vs5.12±0.94）mg/L,the difference had statistical sigificance(P<0.01). In the control group the visfatin and chemerin levels had fewerdecrease after treatment（7.02±0.77vs6.19±0.75）ng/mL，（223.78±0.96vs217.03±6.10）pg/L,the difference had no statistical significant (P>0.05),thelevels of hs-CRP were significantly lower than before （12.92±1.31vs7.39±1.18）mg/L, the difference had statistical sigificance (P<0.01).Serumstimulated with visfatin, chemerin and hs-CRP levels in patients with ACSapplication salvianolate after treatment was significantly lower than thecontrol group（2.96±0.17vs0.82±0.12）ng/mL、（20.09±1.24vs6.42±0.73）pg/L、（9.02±0.24vs5.54±0.19） mg/L, had a statistically significantdifference(P<0.01).Conclusion: This study shows that compared with conventional drugtherapies, giving salvianolate can significantly reduced the serum visfatin,chemerin and hs-CRP concentrations in patients after treatment, indicating thatanti-inflammatory effects of salvianolate comprehensive regulation of the ASpart of the inflammatory response, stable plaques, adjust fat cellsmetabolize,improve cardiac circulation. |
PDF Full Text Request